person

Saskia K.

Country
The Netherlands
Department
Hematology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
79
Sites with multiple studies

Has run more than one trial at 79 of 324 partner sites.

Specializations

Lymphoma Research

This investigator specializes in the treatment of follicular lymphoma, with particular emphasis on developing therapeutic approaches for patients with relapsed or refractory disease conditions. Their research encompasses novel combination therapies including epcoritamab with established treatments.

  • Relapsed/Refractory Follicular Lymphoma
  • Combination Therapy Approaches
  • Immunotherapy Integration

Their work explores the efficacy and safety profiles of innovative treatment combinations in lymphoma care.

B-Cell Malignancies

The investigator focuses on advancing treatment options for B-cell lymphoma, particularly in comparing novel therapeutic agents against standard-of-care chemotherapy regimens. Their research evaluates alternative treatment strategies for resistant disease.

  • Comparative Treatment Studies
  • Novel Therapeutic Approaches
  • Treatment Resistance

Their research aims to establish more effective treatment pathways for B-cell lymphoma patients.

Hodgkin Lymphoma

The investigator conducts research in advanced-stage Hodgkin lymphoma, focusing on optimizing treatment protocols and reducing therapy-related complications. Their work examines innovative treatment combinations and their impact on patient outcomes.

  • Treatment Protocol Optimization
  • Toxicity Reduction Strategies
  • PET-Guided Therapy

Their research evaluates new therapeutic regimens aimed at improving treatment efficacy while minimizing side effects.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.